Volume 17 Supplement 1

British Society of Breast Radiology Annual Scientific Meeting 2015

Open Access

Breast biopsy in patients on anti-coagulants: is new guidance needed?

  • Trupti Kulkarni1, 2 and
  • Andrew O'Connor1
Breast Cancer Research201517(Suppl 1):P33


Published: 5 November 2015


Patients on anti-coagulation requiring breast biopsies are more at risk of bleeding. Newer anti-coagulants may not have a method for quantifying coagulation unlike the INR for warfarin. Also, some of these such as dabigatran do not have antidotes and rely on the body's ability to excrete the drug which may be altered by renal function. There are no up-to-date national guidelines on breast biopsy in such patients.


A questionnaire for assessing practise of breast biopsy in patients on various anti-coagulants was devised. Responses were collected and analysed via Survey Monkey.


Seventy-eight complete responses were received and analysed. Thirty-eight per cent of respondents said they had local guidelines while 45 % used BSBR guidelines 2012. Sixty-three per cent would refer back to the GP/specialist in cases of warfarinised patients,14 % in cases of patients on clopidogrel and only 1 % of those on aspirin. Eighty-eight per cent of respondents did not have a policy for dabigatran and rivaroxaban. Practise was different in screening and symptomatic groups in 7 % due to the site of screening units away from A/E. Unit policy in warfarinised patients requiring vacuum-assisted biopsy (VAB) was not available to 38 %. Anecdotally, a number of radiologists reported that they would not perform VAB in patients on clopidogrel.


There is a wide variation in practise while performing biopsies in patients on anti-coagulation including the newer anti-coagulants.

Authors’ Affiliations

University Hospital Aintree
Clatterbridge Breast Unit


© Kulkarni and O'Connor; 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.